Reimagining Genomics Data Analysis: Interview with Paolo Di Tommaso from Seqera Labs
With BioNTech’s recent $200 million merger with OncoC4’s cancer drug, the demand for personalised medicines to treat diseases such as cancer continues to grow. Much of this development stems from pharmaceutical biotech companies sharing their cutting-edge bioinformatics data on open-source platforms for others to use.
Here is our interview with Paolo Di Tommaso, CTO & Co-founder of Seqera Labs which has a global community of over 15,000 researchers, where we talk about this largely unreported trend. Its flagship product, Nextflow, facilitates this approach to ‘open science’ and is the de facto software of its kind, transforming the way the sector approaches sharing and analysing data. Seqera Labs works with some of the largest pharmaceutical, life sciences and genomics companies worldwide – including AstraZeneca, Janssen Pharmaceuticals, Oxford Nanopore.
Paolo explains how having access to the necessary infrastructure to analyse genomic datasets at scale is speeding up innovation at the earliest levels of scientific research and what this trend means in terms of the scientists behind them, working together.
Topics: AI & Digital
